Legend Biotech Corporation, the majority-owned cell therapy arm of Hong Kong-based life science firm Genscript Biotech, has entered into an agreement to raise about $150.5 million, according to a regulatory filing with the Hong Kong Stock Exchange (HKEX) on March 31.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
